5Pierga JY, Mouret E, Dieras V, et al. Prognostic value of persistent node involvement after neoadjuvant chemotherapy in patients with operable breast cancer[J]. BrJ Cancer, 2000, 83(11): 1480～1487.
6Chollet P, Charrier S, Brain E, et al. Clinical and pathological response to primary chemotherapy in operable breast cancer[J].EurJ Cancer, 1997, 33(6): 862～866.
7Fisher B, Bryant J, Wolmark N, et al. Effect of pre-operative chemotherapy on the outcome of women with operable breast cancer[J].J Clin Oncol, 1998, 16(8): 2672～2685.
8Van der Hage JA, van de Velde CJ, Julien JP, et al. preoperative chemotherapy in primary operable breast cancer:Results from the European organization for research and treatment of cancer trial 10902[J].J Clin Oncol, 2001, 19(22): 4224～4237.
9Koh E, Ueda Y, Nakamura T, et al. Apoptosis in young rats with adriamycin-induced cardiomyopathy-comparison with pirarubicin, a new anthracycline derivative [J]. Pediatr Res, 2002, 51 (2):256 ～259.
4Herait P, Poutignat N, Marty M, et al.Early assessment of a new anticancer drug analogue are the historical comparisons obsolete? The French Experience with pirarubicin[J]. Eur J Cancer, 1992,28A:1670.
5Brincker H. Distant recurrence in breast cancer. Survival expectations and first choice of chemotherapy regimen[J]. Acta Oncol,1988,27(6A) :729-732.
6Tominage T. A randomized controlled study of ( 2''R )-4'-O-tetrahydropy-ranyladriamycin and adriamycin in combination with cyclophosphamide and 5-fluorouracil in the treatment of advanced and recurrent breast cancer.Clinical Study Group of THP for Breast Cancer in Japan [J]. Biomed-pharmacother, 1989,43 (4):271 - 278.
7Tatuo S,Yoichi K,Akira W,et al. Multi-insitutional cooperative study. Phase Ⅱ study of (2''rR)-4-O-tetrahy dropyrany-ladriamycin (THP) in patients with solid tumors [J]. Jpn J Cancer Chemother, 1986,13 (4) : 1060.
5MIEOG J S,VAN DER HAGE J A,VAN DE VIJUER M J,et al.Tumour response to preoperative anthracycline-based chemotherapy in operable breast cancer:the predictive role of p53 expression[J].Eur J Cancer,2006,42(10):1369-1379.
6KIMMICK G G,CIRRINCIONE C,DUGGAN D B,et al.Fifteen-year median follow-up results after neoadjuvant doxorubicin,followed by mastectomy,followed by adjuvant cyclophosphamide,methotrexate,and fluorouracil (CMF) followed by radiation for stage Ⅲ breast cancer:a phase Ⅱ trial (CALGB 8944)[J].Breast Cancer Res Treat,2009,113(3):479-490.
7DAVIDSON A,GELMON K.Do anthracyclines still have a role in adjuvant chemotherapy of breast cancer?[J].Future Oncol,2011,7(1):37-55.
8PRITCHARD K I,SHEPHERD L E,O′MALLEY F P,et al.HER2 and responsiveness of breast cancer to adjuvant chemotherapy[J].N Engl J Med,2006,354(20):2103-2111.
9CASTRELLON A B,GLCK S.Adjuvant therapy for HER2 positive breast cancer:are anthracyclines still necessary?[J].Clin Adv Hematol Oncol,2008,6(9):666-672.
10CHARFARE H,LIMONGELLI S,PURUSHOTHAM A D.Neoadjuvant chemotherapy in breast Cancer[J].Br J Surg,2005,92(1):14-23.
